Group 1 - Edge Total Intelligence Inc. (edgeTI) has approved the issuance of Restricted Stock Units (RSUs) to Lotus Domaine III, LP for consulting services, pending approval by the TSX Venture Exchange [1][2] - The consulting agreement with Lotus will provide edgeTI with guidance on capital market and private equity fundraising, investment opportunities, market positioning, and acquisition targeting from August 29, 2025, to December 31, 2027 [2][3] - A total of 1,593,813 RSUs will be issued as Share-Settled Share Units, vesting one year from the grant date, with an additional grant of 1,145,913 RSUs for the second year of the agreement [3] Group 2 - edgeTI offers real-time digital operations software, edgeCore™, which integrates multiple software applications and data sources to enhance situational awareness and accelerate decision-making for global enterprises, service providers, and governments [4] - The platform's low-code development capability allows customers to improve margins and agility by transforming siloed systems and data across various business and technology domains [4]

Core Insights - Amwell granted RSUs covering 76,198 shares of its Class A common stock to two new employees as an inducement for their employment [1][2] - The RSUs will vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal increments every three months over three years [1] Company Overview - Amwell provides a comprehensive, technology-enabled care platform for payers and health systems, enhancing patient access to affordable and effective care [3] - The platform supports various clinical programs and offers integrated solutions for millions of patients, demonstrating scalability and dependable outcomes [3] - Amwell has been serving major healthcare organizations in the U.S. and globally for nearly two decades [3]

Core Points - Amwell granted 3,451 RSUs of Class A common stock to a new employee as an inducement for employment, with a vesting schedule of 25% after one year and the remaining 75% vesting in equal increments every three months over three years [1][2] - The grants were approved by Amwell's Compensation Committee under the Inducement Plan and comply with NYSE's Listed Company Manual Rule 303A.08 [2] Company Overview - Amwell provides a comprehensive, technology-enabled care platform for payers and health systems, enhancing patient access to convenient, affordable, and effective care [3] - The platform supports various clinical programs and offers integrated solutions that are scalable, serving millions of patients and healthcare organizations globally [3]